An open-label, Phase I/II dose-escalation clinical trial evaluated the safety and efficacy of rAAV2tYF-CB-hRS1, a recombinant adeno-associated virus vector expressing retinoschisin (RS1), in 22 adults and five children with retinal disease caused by mutations in the RS1 gene. This evidence concerns the gene RS1 and Abnormal retinal morphology.